Skip to main content

Events

Canada's Fast-Track Immigration Plan for International Doctors Signals Shift in Physician Workforce Strategy

Image
b2b or b2c?  DÉCLARATION - L'Association médicale canadienne accueille favorablement les nouvelles mesures fédérales visant à accélérer l'intégration des médecins internationaux   News provided by Association médicale canadienne  08 Dec, 2025, 10:14 ET Share this article      OTTAWA, ON, le 8 déc. 2025 /CNW/ - L'Association médicale canadienne (AMC) accueille favorablement l'annonce faite aujourd'hui par Lena Diab, ministre de l'Immigration, des Réfugiés et de la Citoyenneté, concernant de nouvelles mesures

SHERIDAN, WYOMING - December 8, 2025 - Canada is moving to tighten the link between immigration policy and health system capacity, with the federal government announcing new measures to accelerate the arrival and integration of internationally trained physicians-and the Canadian Medical Association (CMA) signalling that the real prize will be pairing these policies with faster, more predictable credential recognition.

New Federal Pathways Aim to Bring Doctors into Practice Faster

In Ottawa, Immigration, Refugees and Citizenship Minister Lena Diab unveiled a package of measures to make it easier for international doctors to settle and work in Canada. The initiative includes a new fast-track entry program for foreign physicians currently working in the country on a temporary basis, as well as additional slots dedicated to doctors under the Provincial Nominee Program.

Philippines E-Visa Rollout in China Targets Faster Growth for Travel Trade Partners

Image
Philippines E-Visa Rollout in China Targets Faster Growth for Travel Trade Partners

SHERIDAN, WYOMING - December 8, 2025 - The Philippines is stepping up its outreach to China's travel industry with a dedicated e-visa training roadshow, as Manila moves to make short-stay tourism and business travel easier and more predictable for Chinese visitors - and to give tour operators, OTAs and consolidators a clear operational playbook ahead of the next wave of demand.

Shenyang Training Puts Front-Line Travel Sellers in Focus

In Shenyang, the Philippine Embassy in China and the Philippine Department of Tourism (PDOT) co-hosted the "菲常旅程,E触即行" e-visa training for the local travel trade, drawing agency representatives and distribution partners from across the region. The session served both as a policy briefing and as a hands-on workshop, designed to ensure that front-line sellers understand eligibility, processes and system workflows.

Global Business Districts Rebound as Frankfurt's Banking Quarter Tops Sustainability Rankings

Image
Global Business Districts Rebound as Frankfurt’s Banking Quarter Tops Sustainability Rankings

SHERIDAN, WYOMING - December 8, 2025 - Global business districts are regaining their pull as hubs for capital, talent and innovation, even as they face structural shifts from hybrid work, rising costs and climate pressures, according to the new "Global Business Districts Attractiveness Report 2025" by EY, the Urban Land Institute (ULI) and the Global Business Districts (GBD) Innovation Club. The study again crowns New York as the world's leading hub while placing Frankfurt's banking district in the global top ten and at number one worldwide for sustainability.

New York Leads, Frankfurt Enters Top Ten as Europe Loses Ground on Scale

Perrigo Faces Securities Class Action Over Baby Formula Unit as Schall Law Firm Seeks PRGO Lead Plaintiffs

Image
Perrigo Faces Securities Class Action Over Baby Formula Unit as Schall Law Firm Seeks PRGO Lead Plaintiffs

SHERIDAN, WYOMING - December 8, 2025 - Investors in Perrigo Company plc (NYSE: PRGO) are weighing next steps after The Schall Law Firm announced a putative securities class action alleging the consumer healthcare company misled the market about the condition and turnaround costs of the baby formula business it acquired from Nestlé. The case highlights ongoing governance and disclosure risk around carved-out assets in regulated consumer categories.

Allegations Center on Underinvestment in Nestlé Baby Formula Business

AGIBOT Marks 5,000th Humanoid Robot as Embodied AI Moves into Real-World Operations

Image
AGIBOT Marks 5,000th Humanoid Robot as Embodied AI Moves into Real-World Operations

SHERIDAN, WYOMING - December 8, 2025 - AGIBOT has reached a key industrialization milestone with the rollout of its 5,000th mass-produced humanoid robot at its Shanghai factory, signaling that embodied AI is moving beyond pilots and demos into scaled deployment across manufacturing, logistics and service environments.

From R&D to Scaled Production Across Three Robot Families

The milestone reflects years of work on stability, reliability and durability in embodied robotics systems. AGIBOT's portfolio now spans three mass-produced humanoid platforms, each tailored to distinct use cases and deployment environments.

Tuhk Raises US$6 Million to Build a Real-Time Anti-Fraud Collaboration Network for Global Payments

Image
Tuhk Raises US$6 Million to Build a Real-Time Anti-Fraud Collaboration Network for Global Payments

SHERIDAN, WYOMING - December 8, 2025 - Canadian fintech Tuhk Inc. is stepping out of stealth with a US$6 million seed round to turn fragmented fraud data into a real-time collaboration fabric between merchants, banks and service providers, as the payments industry wrestles with a cybercrime threat measured in the trillions of dollars.

Fintech Veterans Target a US$10.5 Trillion Cybercrime Problem

Founded in 2025 by veterans from Ethoca and NuData Security, Toronto-based Tuhk is positioning itself as a "real-time data collaboration platform" at the intersection of fraud prevention and payments optimization. The seed financing is led by FINTOP, with strategic participation from Lloyds Banking Group and Capital One Ventures, signalling early alignment from major issuers and card partners.

ANGA COM 2026 Puts Municipalities, In-House Networks and Interactivity at the Center of Europe's Broadband Debate

Image
ANGA COM 2026 Puts Municipalities, In-House Networks and Interactivity at the Center of Europe’s Broadband Debate

SHERIDAN, WYOMING - December 8, 2025 - ANGA COM 2026 is positioning itself as a central meeting point for Europe's broadband, media and connectivity ecosystem, adding new formats for municipalities, in-house networks and interactive round tables while confirming Federal Minister for Digital Transformation and Government Modernisation Dr. Karsten Wildberger as keynote speaker at the opening in Cologne on May 19, 2026.

Federal Minister Headlines Gigabit Summit at Opening

Federal Minister Dr. Karsten Wildberger will open ANGA COM 2026 with a keynote address and then join the traditional Gigabit Summit, where CEOs of leading German telecommunications companies debate the sector's most pressing challenges. His early confirmation underscores ANGA COM's role as a high-level platform where policy, regulation and industry strategy meet, bringing together the broader telecommunications sector with the digital media world.

Teleste Strengthens Public Safety and Mobility Delivery with New Head of Project Management

Image
Teleste Strengthens Public Safety and Mobility Delivery with New Head of Project Management

SHERIDAN, WYOMING - December 8, 2025 - Teleste is sharpening its execution muscle in the fast-growing public safety and mobility market by appointing project delivery specialist Jaakko Keski-Nisula as Head of Project Management for its Public Safety and Mobility business unit, a new leadership role designed to boost delivery performance on complex, safety-critical infrastructure projects.

New leadership role targets large, complex public transport projects

Based in Turku, Finland, Keski-Nisula will join the business unit's Leadership Team and report to Senior Vice President Public Safety and Mobility, Valerian Sand. His remit: strengthen Teleste's project management capabilities across international deployments in public transport and security, where customers increasingly expect turnkey, integrated solutions with predictable timelines and service levels.

Rare Disease Leaders Warn FDA: Innovation Needs Predictable Rules, Not One-Off Exceptions

Image
Rare Disease Leaders Warn FDA: Innovation Needs Predictable Rules, Not One-Off Exceptions

SHERIDAN, WYOMING - December 8, 2025 - After a year of mixed signals from U.S. regulators, rare disease executives and policy experts are urging the FDA to match its pro-innovation rhetoric with clearer, more consistent rules for approvals, arguing that uncertainty around evidence standards is starting to chill investment and slow the next wave of therapies.

Mixed Messages from an Activist, Rare-Disease-Friendly FDA

Under Commissioner Marty Makary and CBER director Vinay Prasad, the FDA has made high-profile statements in favor of easing market access for rare disease treatments and even floated a "plausible mechanism" pathway for ultrarare conditions. Yet in practice, sponsor experience has been uneven.

FDA's One-Trial Plan Could Rewrite Global Drug Development Economics

Image
FDA’s One-Trial Plan Could Rewrite Global Drug Development Economics

SHERIDAN, WYOMING - December 8, 2025 - The U.S. Food and Drug Administration is preparing a fundamental shift in its evidentiary standards for new drugs, with Commissioner Marty Makary signaling that a single pivotal trial could soon be sufficient for approval-a move that has roiled internal leadership, unsettled some regulators and analysts, and triggered immediate recalculations in biopharma portfolio models.

From Two Pivotal Trials to One: A Structural Break

FDA Clinical Hold on Denali's Brain-Penetrant Pompe Therapy Highlights First-in-Human Safety Scrutiny

Image
FDA Clinical Hold on Denali’s Brain-Penetrant Pompe Therapy Highlights First-in-Human Safety Scrutiny

SHERIDAN, WYOMING - December 8, 2025 - Denali Therapeutics is facing another regulatory setback after the U.S. Food and Drug Administration (FDA) placed a clinical hold on DNL952, its enzyme replacement candidate for Pompe disease, citing preclinical hypersensitivity signals and demanding protocol changes before the company can start Phase I studies.

FDA Flags Hypersensitivity Risk Before First Human Dosing

The clinical hold, disclosed in an SEC filing, stems from "hypersensitivity reactions" observed in mouse models. While the agency has not required additional non-clinical studies, it is insisting on a more conservative first-in-human plan. Denali has been asked to lower the proposed starting dose for DNL952 and implement "revised inclusion criteria, adjusted stopping rules and unspecified safety monitoring commitments" before the program can proceed.

Praxis Scores Phase II Win in Rare Epilepsies as Ulixacaltamide Tracks Toward 2026 FDA Filing

Image
Praxis Scores Phase II Win in Rare Epilepsies as Ulixacaltamide Tracks Toward 2026 FDA Filing

SHERIDAN, WYOMING - December 8, 2025 - Praxis Precision Medicines has doubled down on its neurology strategy with back-to-back updates: a Phase II win for its sodium current blocker relutrigine in rare developmental and epileptic encephalopathies (DEE) and a "successful" pre-NDA meeting for its essential tremor candidate ulixacaltamide, positioning the Boston biotech as a potential new commercial player in both ultra-rare epilepsy and movement disorders.

Relutrigine Study Stopped Early for Efficacy in DEE

Praxis has halted its mid-stage EMBOLD trial of relutrigine early, after an independent data monitoring board recommended the study "stop the study early for efficacy." The Phase II EMBOLD study is evaluating relutrigine in patients with DEE linked to SCN8A and SCN2A mutations, a small but highly underserved genetic epilepsy population with limited therapeutic options and high unmet medical need.

Eisai Doubles Down on Tau as Alzheimer's R&D Broadens Beyond Amyloid

Image
Eisai Doubles Down on Tau as Alzheimer’s R&D Broadens Beyond Amyloid

SHERIDAN, WYOMING - December 8, 2025 - Days after Johnson & Johnson reported a mid-stage failure for its anti-tau antibody posdinemab, Eisai is using the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference to argue that tau is still a viable target-if drug designers hit the right part of the protein-while investors and scientists pivot their attention to inflammation and vascular pathways.

Anti-tau Setbacks Raise the Bar for New Entrants

Tau-directed drugs have been among the most high-profile disappointments in Alzheimer's disease (AD) R&D. J&J's recent miss with posdinemab follows last year's Phase II failure of UCB's bepranemab and Eli Lilly's inability to replicate its amyloid success with the anti-tau candidate LY3372689. Collectively, these readouts have fed a narrative that tau may be an intractable or poorly understood target for disease modification.

ACIP's Hepatitis B Birth-Dose Reversal Puts U.S. Newborn Vaccine Policy Under Strain

Image
ACIP’s Hepatitis B Birth-Dose Reversal Puts U.S. Newborn Vaccine Policy Under Strain

SHERIDAN, WYOMING - December 8, 2025 - The CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a major shift in U.S. newborn immunization policy, voting 8-3 to delay the hepatitis B vaccine for infants born to hepatitis B-negative mothers from the traditional birth dose to two months of age, despite decades of evidence and CDC messaging that the shot is safe, effective and critical for long-term protection.

A Narrow Vote to Delay the Birth Dose for Some Newborns

Under the new recommendation, only babies born to mothers who test positive for hepatitis B-or whose status is unknown-would still receive the birth dose. For infants of mothers who test negative, the vaccine can be delayed until two months, effectively dismantling the universal birth-dose strategy that has been in place for about 30 years.

SprintRay's EnvisionTEC Dental Acquisition Signals a New Phase in 3D Printing Consolidation

Image
SprintRay’s EnvisionTEC Dental Acquisition Signals a New Phase in 3D Printing Consolidation

SHERIDAN, WYOMING - December 8, 2025 - SprintRay's acquisition of the EnvisionTEC dental product portfolio marks a strategic step in the consolidation of the dental 3D printing market, expanding its materials ecosystem, reinforcing supply resilience and giving both SprintRay and EnvisionTEC users clearer long-term pathways in digital production.

What Changes for SprintRay Customers: More Materials, Same Workflow

For existing SprintRay practices and labs, the immediate impact is about breadth rather than disruption. The EnvisionTEC dental portfolio brings additional validated resin formulations that SprintRay is adapting for its own printers, which means customers gain more material options without having to invest in new hardware.

How In-House 3D Printing Turns Your Dental Lab from Vendor into Strategic Partner

Image
How In-House 3D Printing Turns Your Dental Lab from Vendor into Strategic Partner

SHERIDAN, WYOMING - December 8, 2025 - As more practices adopt chairside 3D printing, many clinicians worry quietly about what it means for long-standing dental lab relationships-but rather than replacing labs, in-house production is reshaping them into higher-value, more strategic partnerships built around clearly defined roles and shared digital workflows.

From Full Lab Dependency to Hybrid Production

For years, the dominant model in restorative and appliance production has been full lab dependency: every crown, bridge, model, surgical guide, night guard or retainer went out the door to a third-party provider. In that setup, "Lab controls your timeline. Lab controls your cost per case. Lab capacity limits your capacity. Emergency cases wait on lab availability."

How Chairside 3D Printing with SprintRay Rewrites the Economics of Restorative Dentistry

Image
How Chairside 3D Printing with SprintRay Rewrites the Economics of Restorative Dentistry

SHERIDAN, WYOMING - December 8, 2025 - Chairside 3D printing has moved from conference buzzword to everyday reality in U.S. dental practices, and SprintRay is positioning its ecosystem as a way for clinics to bring production in-house, compress treatment timelines, and turn same-day crowns into a strategic differentiator rather than a marketing slogan.

From Lab Dependency to In-Practice Production

At its core, "chairside" simply means producing the restoration in your own practice while the patient is still in your care, instead of sending cases to an external lab and waiting one to two weeks. Clinically, the workflow is familiar-examination, preparation, design and cementation remain the same-but the fabrication step moves from a third party you can't control to equipment in your operatory that you can.

HEIDELBERG's 1,000th Speedmaster CX 104 Powers Hoifu Group's Push Into China's Premium Packaging Segment

Image
HEIDELBERG’s 1,000th Speedmaster CX 104 Powers Hoifu Group’s Push Into China’s Premium Packaging Segment

SHERIDAN, WYOMING - December 8, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) has reached a major milestone with the delivery of its 1,000th Speedmaster CX 104 press, a 14-unit specialty configuration bound for the fast-growing Chinese packaging printer Hoifu Group, underscoring strong demand for high-performance, value-optimized presses in the premium packaging market.

Global Bestseller Targets High-End Packaging Growth in China

The Speedmaster CX 104 has become the bestseller in HEIDELBERG's portfolio thanks to its attractive price-performance ratio and broad suitability for commercial and packaging applications. The landmark 1,000th unit will be installed at Hoifu Group's new site in Yancheng, where it will run as part of an end-to-end, Prinect-based workflow.

HEIDELBERG's First Print Technology World Championship Puts Young Talent Center Stage

Image
HEIDELBERG’s First Print Technology World Championship Puts Young Talent Center Stage

SHERIDAN, WYOMING - December 8, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) is turning its "Home of Print" into a global showcase for the next generation of printers, using the first Print Technology World Championship to promote the attractiveness of print careers and strengthen the industry's long-term skills pipeline.

World Championship Turns the "Home of Print" into a Live Skills Arena

In November, HEIDELBERG and the Swiss Printing and Media Association jointly hosted the inaugural "Print Technology World Championship" for young printing professionals at the Print Media Center at the Wiesloch-Walldorf site. The competition was explicitly aimed at emerging talent and designed to draw attention to the relevance of print as a modern, technology-driven profession.

Kellanova's "Cool Soil Critters" Campaign Puts Soil Health at the Heart of Australia's Food Supply

Image
Kellanova’s “Cool Soil Critters” Campaign Puts Soil Health at the Heart of Australia’s Food Supply

SHERIDAN, WYOMING - December 8, 2025 - Kellanova is using its "Cool Soil Critters" campaign in Australia to turn an often invisible topic-soil health-into a mainstream sustainability and supply-chain conversation, linking biodiversity beneath the surface directly to crop resilience, food security and long-term brand value.

From Iconic Foods to the Health of the Soil Behind Them

As a company that depends on crops to make the foods people know and love, Kellanova is positioning soil health as a strategic asset rather than a purely agronomic concern. Through its partnership with the Cool Soil Initiative, Kellanova Australia and New Zealand (ANZ) is supporting programs that help farmers increase organic carbon levels and reduce greenhouse gas emissions on Australian farms.